THE JOURNAL · ANNUAL REPORT · 2026 EDITION

The State of Psilocybin *in Canada, 2026.*

Where the law stands, how people reach psilocybin lawfully, and what Canadian research is testing: one dated, sourced report with charts you can reuse.

Published 26 October 2026 · Data as of 26 October 2026 (ClinicalTrials.gov, Europe PMC, LEGISinfo); law entries checked 4 October 2026 to 17 October 2026

> **Educational information only.** This report is not medical or legal advice, and nothing in it says what is lawful for you to do.

Key *findings.*

Each finding is one sentence you can quote, with its source.

01 Psilocybin and psilocin are still in Schedule III of the Controlled Drugs and Substances Act, and Health Canada says the production, sale and possession of magic mushrooms are illegal in Canada unless it authorizes them.

Source: Health Canada: Psilocybin and psilocin (magic mushrooms), page dated 2026-10-20 · More: Psilocybin law tracker

02 New federal Controlled Substances Regulations came into force on 1 October 2026; they list psilocin and psilocybin as restricted drugs and do not make magic mushrooms legal.

Source: Controlled Substances Regulations, SOR/2025-242 (Canada Gazette, Part II, 17 December 2025) · More: Are magic mushrooms legal in Canada?

03 Health Canada says there are no approved therapeutic products containing psilocybin, in Canada or elsewhere.

Source: Health Canada: Psilocybin and psilocin (magic mushrooms), page dated 2026-10-20 · More: Psilocybin-assisted therapy in Canada

04 From January 2022 to December 2024, Health Canada's Special Access Program processed 436 requests for psilocybin and authorized 304 (69.7%), according to Health Canada data obtained under Access to Information.

Source: Garel, Plourde, Greenway and Dorval, Nature Mental Health (2025), Health Canada data obtained under Access to Information · More: The Special Access Program, explained

05 The share of those requests authorized fell each year, from 82% in 2022 to 59.1% in 2024, while the number of requests rose from 90 to 181.

Source: Garel, Plourde, Greenway and Dorval, Nature Mental Health (2025), Health Canada data obtained under Access to Information · More: The Special Access Program, explained

06 On 26 October 2026, ClinicalTrials.gov listed 41 psilocybin studies with a site in Canada, 16 of them recruiting.

Source: ClinicalTrials.gov API v2: psilocybin studies with a location in Canada · More: Live trial tracker

07 Toronto is the centre of Canadian psilocybin research: 23 of the 41 studies list a Toronto site, and 31 have a site in Ontario.

Source: ClinicalTrials.gov API v2: psilocybin studies with a location in Canada · More: Psilocybin clinical trials in Toronto

08 Depression is the most-studied condition: 18 of the 41 studies register a depression or mood condition.

Source: ClinicalTrials.gov API v2: psilocybin studies with a location in Canada · More: Psilocybin for depression: the trials

09 Europe PMC indexes 55 MEDLINE papers from 2025 that mention psilocybin in the title or abstract and list a Canadian affiliation, up from 4 in 2020.

Source: Europe PMC REST API search

10 Bill C-286, a private member’s bill on psilocybin, was read a first time on 16 June 2026 and has not reached second reading.

Source: LEGISinfo: Bill C-286 (45th Parliament, 1st session) · More: Bill C-286 explained

SECTION 1

The law *in 2026.*

Federal status. Psilocin and psilocybin are in Schedule III of the Controlled Drugs and Substances Act. Health Canada says the production, sale and possession of magic mushrooms are illegal unless Health Canada authorizes them. New federal Controlled Substances Regulations took effect on 1 October 2026; they list psilocin and psilocybin as restricted drugs and do not make magic mushrooms legal. Bill C-286, a private member's bill about psilocybin, has had only first reading. Health Canada also says that, at this time, there are no approved therapeutic products containing psilocybin in Canada or elsewhere (Health Canada: Psilocybin and psilocin (magic mushrooms), page dated 2026-10-20; Controlled Drugs and Substances Act, Schedule III (Justice Laws); Controlled Substances Regulations, SOR/2025-242 (Canada Gazette, Part II, 17 December 2025)).

Provinces. Federal law applies in every province and territory. Our law tracker has separate entries for the three provinces with something provincial to report; the rest of the country follows the federal position alone.


PSILOCYBIN LAW IN CANADA, BY JURISDICTION, WITH THE NUMBER OF REGISTERED PSILOCYBIN STUDIES THAT HAVE A SITE THERE (CLINICALTRIALS.GOV, 26 OCTOBER 2026)

JURISDICTION	POSITION IN BRIEF	LAWFUL ROUTES	STUDIES WITH A SITE	CHECKED
Canada (federal)	Psilocin and psilocybin are in Schedule III of the Controlled Drugs and Substances Act.	Clinical trials, the Special Access Program (a practitioner's request) and individual section 56(1) exemptions.	41	4 October 2026
Ontario	Federal law applies; Ontario has no exemption or psilocybin therapy framework of its own.	The federal routes only: clinical trials, the Special Access Program and section 56(1) exemptions.	31	4 October 2026
British Columbia	Federal law applies; BC's drug-possession exemption never covered psilocybin and has expired.	The federal routes only: clinical trials, the Special Access Program and section 56(1) exemptions.	8	14 October 2026
Alberta	Federal law applies; since 2023 Alberta also licenses clinics that give psychedelic drug treatment.	The federal routes, delivered under Alberta's clinic rules where they apply.	6	17 October 2026

JURISDICTION	POSITION IN BRIEF	LAWFUL ROUTES	STUDIES WITH A SITE	CHECKED
Other provinces and territories	Federal law applies; no separate provincial framework is recorded in our tracker.	The federal routes only.	Nova Scotia 2; Quebec 2	17 October 2026

REGISTERED PSILOCYBIN STUDIES BY PROVINCE

A study can have sites in several provinces. ClinicalTrials.gov, 26 October 2026.



What changed on 1 October 2026

The Controlled Substances Regulations (SOR/2025-242), published in the Canada Gazette on 17 December 2025, consolidated earlier drug regulations and list psilocin and psilocybin as restricted drugs. The class exemption that supported Special Access Program authorizations was folded into the regulations rather than the route being closed (Controlled Substances Regulations, SOR/2025-242 (Canada Gazette, Part II, 17 December 2025)).

Health Canada updated its psilocybin page on 20 October 2026; some of its guidance pages still pre-date the new regulations. Read the details.

SECTION 2

Access *routes.*

Clinical trials

Health Canada calls clinical trials the most appropriate and effective way to advance research with psilocybin. Each trial needs research ethics board approval (Health Canada: Psilocybin and psilocin (magic mushrooms), page dated 2026-10-20). Health Canada's question-period note of December 2022 said it had approved 16 clinical trials involving psilocybin, 13 of them since the start of 2022 (Health Canada Question Period Note MH-2022-QP-0026 (14 December 2022), Open Government Portal).

Special Access Program


A practitioner, not a patient, can request a drug that is not approved for sale. Requests are assessed case by case and approval is not guaranteed. Practitioner access to psilocybin through the program was restored in January 2022 (Health Canada: Psilocybin and psilocin (magic mushrooms), page dated 2026-10-20). As of 4 November 2022, Health Canada had authorized psilocybin through the program for 50 patients (Health Canada Question Period Note MH-2022-QP-0026 (14 December 2022), Open Government Portal).

Section 56(1) exemptions

A discretionary power of the Minister to exempt a person from the Act for scientific, medical or public-interest purposes; Health Canada says the other routes should generally be pursued first (Health Canada: Psilocybin and psilocin (magic mushrooms), page dated 2026-10-20). The Minister refused a group of practitioners' requests on 9 June 2022 (Health Canada Question Period Note MHA-2022-QP-0003 (14 December 2022)), and in June 2025 the Federal Court of Appeal sent that decision back. We found no official total of exemptions granted. Section 56, explained.

SPECIAL ACCESS PROGRAM: PSILOCYBIN REQUESTS AND AUTHORIZATIONS

Health Canada data obtained under Access to Information, reported by Garel, Plourde, Greenway and Dorval, Nature Mental Health (2025), Health Canada data obtained under Access to Information. Requests, not patients.



Across 2022 to 2024 the program processed 436 psilocybin requests and authorized 304, or 69.7%. Requests doubled between 2022 and 2024 while the share authorized fell from 82% to 59.1%.

Health Canada itself has not published newer psilocybin figures that we could find. The 2022 question-period note counts *patients* (50 by 4 November 2022), while the Access to Information figures count *requests*, so the two can't be compared directly. An authorization is permission to supply, not evidence that treatment happened or worked.

SECTION 3

Clinical *research.*

41
studies with a Canadian site

16
recruiting


13
not yet recruiting or under way

21
cities in 5 provinces

ClinicalTrials.gov API v2, intervention “psilocybin”, location “Canada”, fetched 26 October 2026. 7 studies are completed; 36 of 41 registered start dates fall in 2023 or later, 13 of them in 2026. Planned or actual enrolment across all 41 studies, worldwide, totals 2,724 participants. The registry classes 9 lead sponsors as industry and 32 as other (universities, hospitals, individual investigators and foundations).


BY STATUS

ClinicalTrials.gov, 26 October 2026. “Under way” = active, not recruiting, or enrolling by invitation.




BY PHASE

29 are phase 2 only; 3 include phase 3.




BY CONDITION STUDIED

Our plain-language groups of each study's registered conditions; a study can count in several.



BY START YEAR

Start dates as registered, actual or anticipated. 2026 includes studies not yet started (dashed).



BY CITY

Studies listing at least one site in each city, with city names as the records give them.

LEAD SPONSORS, AS THE RECORDS NAME THEM


Some records name an individual investigator as sponsor; we keep the registry’s wording.

Toronto	23
Calgary	6
Kingston	5
Kelowna	4
Ottawa	3
Vancouver	3
Hamilton	2
London	2
Mississauga	2
Montreal	2
Surrey	2
Abbotsford	1
Brampton	1
Chatham	1
Halifax	1
Kamloops	1
Newmarket	1
North Vancouver	1
Penticton	1
Québec	1
Windsor	1

Centre for Addiction and Mental Health	8
University Health Network, Toronto	5
University of Calgary	5
COMPASS Pathways	3
Unity Health Toronto	2
Brain and Cognition Discovery Foundation	1
Bruyère Health Research Institute.	1
Clairvoyant Therapeutics	1
Claudio N Soares	1
Cybin Therapeutics Inc.	1
Diamond Therapeutics Inc.	1
Empower Research Inc	1
Gustavo Vazquez	1
Halucenex Life Sciences Inc.	1
Joshua Rosenblat	1
Kyle Greenway	1
Lakshmi N Yatham	1
McMaster University	1
Nova Mentis Life Science Corp	1
Ottawa Hospital Research Institute	1
Rotem Petranker	1
Sunnybrook Health Sciences Centre	1
University of British Columbia	1

CANADIAN-AFFILIATED PSILOCYBIN PAPERS PER YEAR

MEDLINE records in Europe PMC with “psilocybin” in the title or abstract and “Canada” in an author affiliation, queried 26 October 2026. 2026 is a part year (dashed).



Canadian-affiliated publications on psilocybin rose from 4 in 2020 to 55 in 2025. Worldwide, the same search found 82 papers in 2020 and 464 in 2025, so Canada’s share was about 12% in 2025.

These are counts of records, not of studies or findings: a review, a protocol and a trial report each count once, and affiliation matching misses records without full affiliation data. See methods.

PSILOCYBIN STUDIES WITH A CANADIAN SITE, CLINICALTRIALS.GOV, 26 OCTOBER 2026

STUDY	STATUS	PHASE	CANADIAN CITIES	LEAD SPONSOR
NCT07570654 Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder	Recruiting	Phase 2 / Phase 3	North Vancouver	COMPASS Pathways
NCT07211438 Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression	Recruiting	Phase 2	Toronto	Centre for Addiction and Mental Health
NCT06943573 Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder	Recruiting	Phase 2	Vancouver, Ottawa, Toronto	Lakshmi N Yatham
NCT06768944 Subjective Experience Following Psilocybin	Recruiting	Phase 2	Calgary	University of Calgary

STUDY	STATUS	PHASE	CANADIAN CITIES	LEAD SPONSOR
NCT06818994 Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer	Recruiting	Phase 1	Kingston	Gustavo Vazquez
NCT07405606 Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder	Recruiting	Phase 2	Toronto	Centre for Addiction and Mental Health
NCT07063862 Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT)	Recruiting	Phase 3	Brampton, Kingston, London, Newmarket, Ottawa, Montreal	Bruyère Health Research Institute.
NCT05585229 Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication	Recruiting	Phase 2	Kelowna	University of British Columbia
NCT07048743 Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Caregivers of Patients With Advanced Cancer	Recruiting	Phase 2	Toronto	University Health Network, Toronto
NCT06072898 A Randomized Neuroimaging Trial of Psilocybin in Depression	Recruiting	Phase 2	Toronto	Sunnybrook Health Sciences Centre
NCT06615908 Treatment of Persisting Symptoms After Concussion With Psilocybin Assisted Therapy	Recruiting	Phase 1	Calgary	University of Calgary
NCT06969170 Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder	Recruiting	Phase 2	Kingston	Claudio N Soares
NCT06512220 Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)	Recruiting	Phase 2	Toronto	Centre for Addiction and Mental Health

STUDY	STATUS	PHASE	CANADIAN CITIES	LEAD SPONSOR
NCT06518720 Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND)	Recruiting	Phase 2	Toronto	Centre for Addiction and Mental Health
NCT06731335 Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN	Recruiting	Phase 2	Toronto	Unity Health Toronto
NCT05995769 Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder	Recruiting	Phase 2	Calgary	University of Calgary
NCT07791901 MB-PAT for Demoralization in Advanced Cancer ('PAT-MIND') Trial	Not yet recruiting	Phase 2	Calgary, Kingston	University of Calgary
NCT06885996 Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence	Not yet recruiting	Phase 2	Calgary, Kelowna	University of Calgary
NCT07820033 Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial	Not yet recruiting	Phase 2	Toronto	University Health Network, Toronto
NCT07373535 Understanding Music and Mindfulness Preferences in Psilocybin-Assisted Psychotherapy	Not yet recruiting	Phase 2	Montreal	Kyle Greenway
NCT07737990 Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression	Enrolling by invitation	Not applicable	Toronto	Joshua Rosenblat
NCT06386003 Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD	Active, not recruiting	Phase 2	Toronto	Unity Health Toronto
NCT06225232 Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study	Active, not recruiting	Phase 2	Hamilton	McMaster University

STUDY	STATUS	PHASE	CANADIAN CITIES	LEAD SPONSOR
NCT06731621 Psilocybin for Treatment-Resistant Depression in Autism	Active, not recruiting	Phase 1	Toronto	Centre for Addiction and Mental Health
NCT06506019 Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression	Active, not recruiting	Phase 1	Toronto	University Health Network, Toronto
NCT06416085 Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer	Active, not recruiting	Phase 2	Toronto	University Health Network, Toronto
NCT06341426 Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin	Active, not recruiting	Phase 2	Toronto	University Health Network, Toronto
NCT04754061 PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL)	Active, not recruiting	Phase 1 / Phase 2	Ottawa	Ottawa Hospital Research Institute
NCT05711940 Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD	Active, not recruiting	Phase 3	Québec, Kamloops, Kelowna, Penticton, Chatham, Toronto, Vancouver	COMPASS Pathways
NCT06299319 Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD	Completed	Phase 1	Toronto	Centre for Addiction and Mental Health
NCT06041152 Does Psilocybin Change Synaptic Density in Amnestic Mild Cognitive Impairment	Completed	Phase 2	Toronto	Centre for Addiction and Mental Health
NCT05259943 Microdosing Psychedelics to Improve Mood	Completed	Phase 2	Toronto	Rotem Petranker
NCT05710237 Does Psilocybin Require Psychedelic Effects to Treat Depression?	Completed	Phase 2	Toronto	Centre for Addiction and Mental Health

STUDY	STATUS	PHASE	CANADIAN CITIES	LEAD SPONSOR
NCT05029466 Psilocybin for Treatment-Resistant Depression	Completed	Phase 2	Mississauga	Brain and Cognition Discovery Foundation
NCT07710027 Identification of a Safe and Non-Psychedelic Dose of Psilocybin	Completed	Phase 1	Toronto	Diamond Therapeutics Inc.
NCT03775200 The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression	Completed	Phase 2	Mississauga, Toronto	COMPASS Pathways
NCT05832255 An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome	Suspended	Phase 2	London	Nova Mentis Life Science Corp
NCT05594667 Effect of SSRIs on Response to Psilocybin Therapy	Withdrawn	Phase 2	Abbotsford	Cybin Therapeutics Inc.
NCT06471959 Psychedelic-assisted Group Program for First Responders	Status unknown	Phase 1 / Phase 2	Surrey	Empower Research Inc
NCT05243329 Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder	Status unknown	Phase 2	Windsor	Halucenex Life Sciences Inc.
NCT05646303 Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)	Status unknown	Phase 2	Calgary, Kelowna, Surrey, Vancouver, Halifax, Hamilton, Kingston, Toronto	Clairvoyant Therapeutics

The live trial tracker refreshes from the registry daily; this report keeps the 26 October 2026 snapshot so its numbers stay fixed.

SECTION 4

Canada *vs the world.*

Canada sits with most countries in our tracker: psilocybin is controlled, with research and case-by-case exceptions. What sets other places apart is a defined route that Canada does not have, such as a state-licensed adult program or a prescribing rule for one condition.

TYPES OF RULE, PLACE BY PLACE

From our law tracker, entries checked 4 October 2026 to 17 October 2026. A place can have more than one type.



Oregon

SUPERVISED ADULT-USE PROGRAM

State-licensed psilocybin services for adults 21 and over, at licensed service centres.

Checked 10 October 2026 · Oregon Health Authority: Oregon Psilocybin Services

Colorado

SUPERVISED ADULT-USE PROGRAM

Licensed healing centres plus a personal-use framework for adults 21 and over.

Checked 10 October 2026 · Colorado Natural Medicine Division: About Us

New Mexico

NARROW MEDICAL ROUTE

A state medical psilocybin program was enacted in 2025; the law gives the health department until the end of 2027 to implement it.

Checked 17 October 2026 · SB 219, final enacted version (New Mexico Legislature)

Australia

NARROW MEDICAL ROUTE

Schedule 8 only for treatment-resistant depression, through an authorized psychiatrist or a trial.

Checked 4 October 2026 · Poisons Standard, October 2026 (F2026L01327)

Czech Republic

CONTROLLED, RESEARCH AND EXCEPTIONS ONLY · NARROW MEDICAL ROUTE

Since 1 January 2026, psilocybin can be used medically in authorized psychiatric settings; otherwise it remains controlled.

Checked 17 October 2026 · Act No. 270/2025 Coll. (e-Sbírka, official collection of laws)

New Zealand

CONTROLLED, RESEARCH AND EXCEPTIONS ONLY · NARROW MEDICAL ROUTE

Psilocybin is a Class A controlled drug; a named doctor can be approved to prescribe it, for pharmaceutical-grade product only.


Checked 17 October 2026 · Medsafe: approval to prescribe psychedelics

SECTION 5

Key moments, *2020–2026.*

DATED MOMENTS PER YEAR

From our psilocybin timeline and law tracker; each moment below links to its sourced page.



2020

Health Canada grants individual section 56 exemptions for psilocybin; CBC reported 19 practitioners received exemptions that year. Source page

November 2020

Oregon voters pass Measure 109, creating state-licensed psilocybin services. Source page

January 2022

Practitioners can again request psilocybin through Health Canada's Special Access Program. Source page

9 June 2022

The Minister refuses a group of practitioners' section 56 exemption requests; a court challenge follows on 11 July 2022. Source page

8 November 2022

Colorado's Proposition 122 (Natural Medicine Health Act) is on the ballot and passes. Source page

16 January 2023

Alberta begins requiring a provincial licence for clinics offering psychedelic drug treatment. Source page

Summer 2023

Oregon's licensed psilocybin service centres begin opening to clients. Source page

7 April 2025

New Mexico's Medical Psilocybin Act (SB 219) is signed. Source page

April 2025

Colorado's Natural Medicine Division approves its first healing-centre licence. Source page

June 2025

The Federal Court of Appeal sets aside the 2022 refusals as unreasonable and sends them back to the Minister. Source page

17 December 2025

The Controlled Substances Regulations (SOR/2025-242) are published in the Canada Gazette. Source page

1 January 2026

The Czech Republic allows medical use of psilocybin in authorized psychiatric settings. Source page

31 January 2026

British Columbia’s drug-possession exemption, which never covered psilocybin, expires. Source page

16 June 2026

Bill C-286, a private member’s bill on psilocybin, is introduced and read a first time. Source page

1 October 2026

The Controlled Substances Regulations come into force, listing psilocin and psilocybin as restricted drugs. Source page


SECTION 6

What to watch *in 2027.*

Only items with a documented, dated basis. These are not predictions.

REGISTERED PRIMARY COMPLETION DATES

Primary completion as each study registered it (actual or anticipated). ClinicalTrials.gov, 26 October 2026.



11 studies with a Canadian site give a primary completion date in 2027. A completion date is the registry's anticipated date for the last participant's primary measurement, not a date for results.

Bill C-286: first reading on 16 June 2026; LEGISinfo lists it as outside the order of precedence, with second reading not reached (LEGISinfo: Bill C-286 (45th Parliament, 1st session), opened 26 October 2026).

The practitioners' exemption case: in June 2025 the Federal Court of Appeal sent the 2022 refusals back to the Minister. As of 4 October 2026 we found no public redetermination. Details.

Health Canada guidance under the new regulations: its psilocybin page was updated on 20 October 2026 (Health Canada: Psilocybin and psilocin (magic mushrooms), page dated 2026-10-20), but when we re-read them on 24 October its Special Access Program and class-exemption pages still pre-dated 1 October 2026. Details.

New Mexico: the Medical Psilocybin Act sets 31 December 2027 as the deadline to implement the state program. Law tracker.

COMP360 (company statement): on 5 August 2026 Compass Pathways said its rolling application to the US FDA was expected to be completed in the fourth quarter of 2026. A US decision would not authorize the drug in Canada, which needs its own Health Canada review. Details.

STUDIES WITH A CANADIAN SITE AND A REGISTERED PRIMARY COMPLETION DATE IN 2027

PRIMARY COMPLETION	STUDY	STATUS	PHASE	LEAD SPONSOR
January 2027	NCT06731621 Psilocybin for Treatment-Resistant Depression in Autism	Active, not recruiting	Phase 1	Centre for Addiction and Mental Health
March 2027	NCT06518720 Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND)	Recruiting	Phase 2	Centre for Addiction and Mental Health
April 2027	NCT06512220 Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)	Recruiting	Phase 2	Centre for Addiction and Mental Health
1 June 2027	NCT06818994 Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer	Recruiting	Phase 1	Gustavo Vazquez
30 June 2027	NCT06615908 Treatment of Persisting Symptoms After Concussion With Psilocybin Assisted Therapy	Recruiting	Phase 1	University of Calgary
August 2027	NCT07063862 Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT)	Recruiting	Phase 3	Bruyère Health Research Institute.
1 October 2027	NCT05995769 Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder	Recruiting	Phase 2	University of Calgary
December 2027	NCT06768944 Subjective Experience Following Psilocybin	Recruiting	Phase 2	University of Calgary
2 December 2027	NCT07048743 Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Caregivers of Patients With Advanced Cancer	Recruiting	Phase 2	University Health Network, Toronto
20 December 2027	NCT07791901 MB-PAT for Demoralization in Advanced Cancer ('PAT-MIND') Trial	Not yet recruiting	Phase 2	University of Calgary

PRIMARY COMPLETION	STUDY	STATUS	PHASE	LEAD SPONSOR
31 December 2027	NCT06969170 Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder	Recruiting	Phase 2	Claudio N Soares

SECTION 7

Methods *and sources.*

How the data was gathered

Clinical studies. We queried the ClinicalTrials.gov API v2 on 26 October 2026 (14:09 UTC) for studies with "psilocybin" as an intervention and a location in Canada, and saved the answer. All 41 returned records list at least one Canadian site. Status, phase, conditions, dates, sites and sponsors are the registry's own; we only grouped conditions into plain-language buckets and merged spellings of province names.

Research output. Europe PMC REST API hit counts on 26 October 2026, for MEDLINE records (SRC:MED) with "psilocybin" in the title or abstract, per publication year, with and without "Canada" in an author affiliation (AFF:Canada). Example query (2025).

Law. From our law tracker, where each entry restates official texts and carries its own check date (4 October 2026 to 17 October 2026). We re-read Health Canada's psilocybin page and LEGISinfo's record of Bill C-286 on 26 October 2026.

Access figures. Health Canada's question-period note of 14 December 2022 (opened 26 October 2026), and Health Canada data obtained under Access to Information as reported in a 2025 peer-reviewed comment (Garel et al.). Health Canada has not published those yearly figures itself, as far as we could find.

Limits

Registry records are entered and updated by each study team; statuses and dates can be out of date. Start and completion dates may be anticipated rather than actual.

A location search finds studies that list a Canadian site; it misses Canadian-led studies that run only abroad, and studies not registered on ClinicalTrials.gov. Health Canada's own clinical trials database is a separate source and does not line up exactly.

Enrolment totals are each study's planned or actual number across all its sites, not participants in Canada.

Records can contain entry errors. One multi-site record (NCT05711940) lists its Québec site with the province "B.C."; we count provinces as the records give them, and that study has British Columbia sites as well.

Affiliation matching in Europe PMC depends on the affiliation data each record carries, so counts are a floor; the most recent months are still being indexed.

Special Access Program figures count requests, and end in December 2024.

Sources

Health Canada: Psilocybin and psilocin (magic mushrooms), page dated 2026-10-20

Controlled Drugs and Substances Act, Schedule III (Justice Laws)

Controlled Substances Regulations, SOR/2025-242 (Canada Gazette, Part II, 17 December 2025)

Health Canada Question Period Note MH-2022-QP-0026 (14 December 2022), Open Government Portal

Health Canada Question Period Note MHA-2022-QP-0003 (14 December 2022)

Garel, Plourde, Greenway and Dorval, Nature Mental Health (2025), Health Canada data obtained under Access to Information

LEGISinfo: Bill C-286 (45th Parliament, 1st session)

ClinicalTrials.gov API v2: psilocybin studies with a location in Canada

Europe PMC REST API search

How to cite *this report.*

Shroomverse. (2026, October 26). The State of Psilocybin in Canada, 2026. https://www.theshroomverse.com/research/state-of-psilocybin-canada-2026

Link: https://www.theshroomverse.com/research/state-of-psilocybin-canada-2026 · PDF: https://www.theshroomverse.com/research/state-of-psilocybin-canada-2026.pdf

Use our charts

You may reuse the charts and the data tables in this report, in print or online, with credit to “Shroomverse, The State of Psilocybin in Canada, 2026” and a link to this page. Please keep the data date (26 October 2026) with any figure you reuse.
Educational information only, not medical or legal advice. Shroomverse has no connection to any study listed.
Corrections: see our editorial standards or contact us.